Dr. Page on Hormone-Directed Strategies in Triple-Negative Breast Cancer

David B. Page, MD
Published: Thursday, May 31, 2018



David B. Page, MD, medical oncologist, Providence Cancer Center, discusses hormone-directed strategies in the treatment of patients with triple-negative breast cancer (TNBC).

It is not well known whether hormone-directed strategies could be a relevant strategy in treating patients with TNBC, says Page. There are some data that suggest that in about half of patients with TNBC, the expression of androgen receptor is upregulated and could be relevant in the signaling process. Early data have shown that physicians can block androgens.

Page states that there is provocative evidence that physicians can stimulate immune responses and generate new T cells because the thymus, an organ that sits within the chest, is dependent on androgen signaling. If physicians can block that signaling, they may be able to stimulate the production of new T cells, says Page. This is currently being investigated in ongoing clinical trials.
 


David B. Page, MD, medical oncologist, Providence Cancer Center, discusses hormone-directed strategies in the treatment of patients with triple-negative breast cancer (TNBC).

It is not well known whether hormone-directed strategies could be a relevant strategy in treating patients with TNBC, says Page. There are some data that suggest that in about half of patients with TNBC, the expression of androgen receptor is upregulated and could be relevant in the signaling process. Early data have shown that physicians can block androgens.

Page states that there is provocative evidence that physicians can stimulate immune responses and generate new T cells because the thymus, an organ that sits within the chest, is dependent on androgen signaling. If physicians can block that signaling, they may be able to stimulate the production of new T cells, says Page. This is currently being investigated in ongoing clinical trials.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x